Reviewing Icon (NASDAQ:ICLR) and IceCure Medical (NASDAQ:ICCM)

Icon (NASDAQ:ICLR) and IceCure Medical (NASDAQ:ICCM) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership and dividends.

Profitability

This table compares Icon and IceCure Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Icon	5.98%	9.50%	5.40%
IceCure Medical	-441.60%	-211.73%	-119.13%

Risk & Volatility

Icon has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500.

Institutional & Insider Ownership

95.6% of Icon shares are owned by institutional investors. Comparatively, 0.6% of IceCure Medical shares are owned by institutional investors. 44.0% of Icon shares are owned by company insiders. Comparatively, 2.4% of IceCure Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Icon and IceCure Medical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Icon	2	8	8	0	2.33
IceCure Medical	1	1	3	0	2.40

Icon currently has a consensus price target of $156.44, suggesting a potential upside of 4.68%. IceCure Medical has a consensus price target of $62.70, suggesting a potential upside of 1,338.07%. Given IceCure Medical’s stronger consensus rating and higher possible upside, analysts plainly believe IceCure Medical is more favorable than Icon.

Valuation & Earnings

This table compares Icon and IceCure Medical”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Icon	$8.25 billion	1.39	$229.34 million	$6.16	24.26
IceCure Medical	$3.38 million	3.62	-$15.06 million	($7.21)	-0.60

Icon has higher revenue and earnings than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.

Summary

Icon beats IceCure Medical on 11 of the 14 factors compared between the two stocks.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.